Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML1819 phase III study of gemtuzumab ozogamicin added to standard chemotherapy in newly diagnosed favorable/intermediate-risk acute myeloid leukemia
2023-510433-29-00Phase 3Authorised
- Sponsor
- GIMEMA
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by GIMEMA. Primary endpoint: MRD negativity after consolidation. Planned start Sep 2020; status: authorised.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-510433-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510433-29-00.